If this file opens in Compatibility Mode using Microsoft Word, convert to the latest document format to avoid potential formatting issues.	

RSH OP PRO00036433 / SGN70-101 / SCREENING / BASELINE	

Types:      Research Oncology Treatment
Synonyms:  MYELOID MALIGNANCIES, SEA-CD70 , SGN70

Baseline / Screening( 28 Days Prior to C1D1 )	Repeat 1 time	Cycle length: 28 days	Day 1	Perform every 1 day x1			Research tolerance: -7/+1 days	Provider Communication
  	ONC PROVIDER COMMUNICATION 6	Interval: --	Occurrences: --	Comments:	Diagnostic bone marrow exam (must be performed within 4 weeks of C1D1, for establishment of diagnosis for study enrollment).
		  	ONC PROVIDER COMMUNICATION 6	Interval: --	Occurrences: --	Comments:	-Cytogenetics must be locally assessed according to institutional standard. If this test was performed within 8 weeks of C1D1 and the subject has not had subsequent antileukemic treatment, this test does not need to be repeated.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --			Labs
  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --			Labs
  	URINALYSIS, AUTOMATED WITH MICROSCOPY	Interval: --	Occurrences: --			Labs
  	HCG QUALITATIVE, SERUM SCREEN	Interval: --	Occurrences: --		  	HCG QUANTITATIVE, SERUM	Interval: --	Occurrences: --		  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --			Labs
  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --		  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --		  	HEPATITIS C VIRUS (HCV), QUANTITATIVE PCR	Interval: --	Occurrences: --